LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

Inicio・Lista de Acciones・Novo Nordisk A-S

Novo Nordisk A-S

Cerrado

Sector Salud

131.05 0.18

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

130.75

Máximo

131.39

Métricas clave
By Trading Economics
Ingresos	-5.4B 20B
Ventas	2.7B 68B
P/B Media del Sector	49.94 103.001
BPA	4.49
Margen de beneficio	29.459
EBITDA	-1.2B 36B

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+10.38 upside

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	711M 471B
Apertura anterior	130.87
Cierre anterior	131.05

Noticias sobre sentimiento de mercado

By Acuity

100%

331 / 365 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

130.53 / 134.62 Soporte y Resistencia

Novo Nordisk A-S Gráfico

Noticias Relacionadas

7 ago 2024, 10:13 UTC

Ganancias

Novo Nordisk's Wegovy Sales Disappoint -- 2nd Update

7 ago 2024, 06:58 UTC

Ganancias

Wegovy Maker Novo Nordisk Lifts Sales Guidance as Weight-Loss Drug Demand Continues to Surge -- Update

7 ago 2024, 06:10 UTC

Ganancias

Wegovy Maker Novo Nordisk Lifts Sales Guidance as Weight-Loss Drug Demand Continues to Surge

3 sept 2024, 11:09 UTC

Principales Noticias

Novo Nordisk's Says Ozempic Shortage Deteriorates. Why It's Good News For Eli Lilly. -- Barrons.com

27 ago 2024, 05:30 UTC

Principales Noticias

Weight-Loss Drugs Get More Good News. For Investors, It's Still Too Soon to Celebrate. -- Barrons.com

14 ago 2024, 12:01 UTC

Charlas de Mercado

Ganancias

Novo Nordisk's Pricing and Pipeline to Remain Hot Topics -- Market Talk

9 ago 2024, 11:30 UTC

Principales Noticias

Eli Lilly Is Gaining on Novo Nordisk in the Obesity Race -- Heard on the Street -- WSJ

9 ago 2024, 07:30 UTC

Charlas de Mercado

Novo Nordisk Share Pullback Represents Great Opportunity -- Market Talk

8 ago 2024, 15:44 UTC

Principales Noticias

Ganancias

Eli Lilly Shows We Haven't Hit Peak Obesity Yet -- WSJ

8 ago 2024, 11:36 UTC

Charlas de Mercado

Ganancias

Novo Nordisk's Share-Price Weakness Provides an Opportunity -- Market Talk

8 ago 2024, 07:16 UTC

Charlas de Mercado

Ganancias

Novo Nordisk's Share-Price Drop Provides Buying Opportunity -- Market Talk

7 ago 2024, 20:30 UTC

Principales Noticias

Eli Lilly Reports Earnings Thursday Amid a Stock Slump. Here's What to Expect. -- Barrons.com

7 ago 2024, 16:39 UTC

Ganancias

Novo Nordisk's Wegovy Sales Disappoint -- Update

7 ago 2024, 15:30 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Novo Nordisk's Wegovy Sales Disappoint -- WSJ

7 ago 2024, 14:22 UTC

Principales Noticias

Ganancias

It Isn't Time to Worry About Wegovy Yet -- Heard on the Street -- WSJ

7 ago 2024, 12:28 UTC

Charlas de Mercado

Ganancias

Novo Nordisk's Core Products Disappoint -- Market Talk

7 ago 2024, 12:04 UTC

Ganancias

Novo Nordisk Execs Were Speaking on a Call After 2Q Earnings

7 ago 2024, 11:34 UTC

Ganancias

Novo Nordisk US Head: As Wegovy Volumes Go Up, Prices Will Come Down

7 ago 2024, 11:34 UTC

Ganancias

Novo Nordisk CEO: When You Move Into New Sales Channels it Comes With a Discount

7 ago 2024, 11:34 UTC

Ganancias

Novo Nordisk CEO: Wegovy Now Covered in 20 States Through Medicaid

7 ago 2024, 11:05 UTC

Charlas de Mercado

Ganancias

Novo Nordisk Delivers Messy Quarter as Wegovy Misses The Mark -- Market Talk

7 ago 2024, 10:55 UTC

Ganancias

Stock Market Madness Highlights This Problem for -2-

7 ago 2024, 10:55 UTC

Ganancias

Stock Market Madness Highlights This Problem for Novo Nordisk and Super Micro. And 5 Other Things to Know Today. -- Barrons.com

7 ago 2024, 09:07 UTC

Ganancias

Acciones populares

Stocks to Watch Wednesday: Super Micro, Rivian, Airbnb -- WSJ

7 ago 2024, 08:55 UTC

Principales Noticias

These Stocks Are Moving the Most Today: Super Micro, Lumen, Airbnb, Rivian, Fortinet, Upstart, Disney, and More -- Barrons.com

7 ago 2024, 07:32 UTC

Charlas de Mercado

Ganancias

Novo Nordisk Wegovy Sales Disappoint -- Market Talk

7 ago 2024, 05:45 UTC

Ganancias

Novo Nordisk Declares Interim Dividend of DKK3.50

7 ago 2024, 05:44 UTC

Ganancias

Novo Nordisk 2Q Gross Margin 84.9% Vs 85.5%, Op Margin 38.1% Vs 44.0%

7 ago 2024, 05:40 UTC

Ganancias

Novo Nordisk 2Q Wegovy Drug Sales DKK11.66B Vs DKK7.52B

7 ago 2024, 05:38 UTC

Ganancias

Novo Nordisk: Sales Growth Has Resulted in Periodic Supply Constraints, Related Drug Shortage Notifications

Comparación entre iguales

Cambio de precio

Novo Nordisk A-S Esperado

Precio Objetivo

By TipRanks

10.38% repunte

Estimación a 12 meses

Media 144.75 USD 10.38%

Máximo 166 USD

Mínimo 82.5 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Novo Nordisk A-S Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

9 ratings

Comprar

Mantener

Vender

De acuerdo con 9 analistas que ofrecen calificaciones bursátiles a para Novo Nordisk A-S Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

130.53 / 134.62Soporte y Resistencia

Recent bearish events outweigh bullish events.

There is one bullish event.

Sentimiento

By Acuity

331 / 365 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

EBITDA

Beneficio operativo

Acerca de Novo Nordisk A-S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.